Elie Dolgin/Nature photo
(The full text of his testimony can be found here.)
“He has considerable influence with the ICOC(the CIRM governing board), and is closely associated with biotech in the Bay Area. Even if he doesn't make a lot of money himself from this, then he certainly has friends who will. Irv Weissman would be one of those friends."
“(I)t would be a tragedy if the expertise of board members built up over six or more years is lost.”
"StemCells Inc has been on the stock market for 20 years, without producing anything of value for the investors. The stock price has been sinking fast: it was 60 cents this June; last year at this time, it was around $5 a share.
“On July 17, when the CIRM Disease Team Award review results became available, the stock rose from 87 cents to $1.80 – a person who could anticipate the outcome of the CIRM applications could have made considerable money in that 24 hour period.”
(See here for an April 2013 update on the StemCells, Inc., awards.)